Last reviewed · How we verify
ART0380
ART0380 is a DNA-protein crosslink (DPC) repair inhibitor that enhances the activity of DNA damaging agents by preventing cellular repair of crosslinks.
ART0380 is a DNA-protein crosslink (DPC) repair inhibitor that enhances the activity of DNA damaging agents by preventing cellular repair of crosslinks. Used for Advanced solid tumors (in combination with DNA-damaging chemotherapy).
At a glance
| Generic name | ART0380 |
|---|---|
| Sponsor | Artios Pharma Ltd |
| Drug class | DNA repair inhibitor |
| Target | DPC (DNA-protein crosslink) repair pathway |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
ART0380 targets the DPC repair pathway, which cells normally use to remove DNA-protein crosslinks caused by chemotherapy and other DNA-damaging agents. By inhibiting this repair mechanism, the drug potentiates the cytotoxic effects of DNA-damaging therapies, making cancer cells more susceptible to treatment. This approach is designed to improve efficacy of existing chemotherapies and overcome resistance mechanisms.
Approved indications
- Advanced solid tumors (in combination with DNA-damaging chemotherapy)
Common side effects
- Myelosuppression
- Gastrointestinal toxicity
- Fatigue
Key clinical trials
- A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors (PHASE1, PHASE2)
- Study of ART0380 in Patients With Biologically Selected Solid Tumors (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ART0380 CI brief — competitive landscape report
- ART0380 updates RSS · CI watch RSS
- Artios Pharma Ltd portfolio CI